Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

(2021) Chih-Hsi Scott Kuo et al.   BMC CANCER

Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants

(2020) Victoria Allan et al.   Journal of Comparative Effectiveness Research

Synthetic and External Controls in Clinical Trials – A Primer for Researchers

(2020) Kristian Thorlund et al.   Clinical Epidemiology

Real-world evidence and nonrandomized data in health technology assessment: use existing methods to address unmeasured confounding?

(2020) Cormac J Sammon et al.   Journal of Comparative Effectiveness Research

Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes

(2020) John C O’Donnell et al.   Future Oncology

Single-arm Trials With External Comparators and Confounder Misclassification

(2020) Michael Webster-Clark et al.   MEDICAL CARE

How to Deal with the Inevitable: Generating Real-World Data and Using Real-World Evidence for HTA Purposes – From Theory to Action

(2019) Wija Oortwijn et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?

(2018) Daniel C. Malone et al.   VALUE IN HEALTH

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib

(2018) Jessica Davies et al.   Journal of Comparative Effectiveness Research

Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer

(2018) Rachel E. Gemine et al.   LUNG CANCER

Real-world data for efficient health technology assessment

(2017) Peter S. Hall   EUROPEAN JOURNAL OF CANCER

Quantitative Bias Analysis in Regulatory Settings

(2016) Timothy L. Lash et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

(2016) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

(2016) Alice T Shaw et al.   LANCET ONCOLOGY

Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer

(2016) Matthew B. Schabath et al.   Cancer Control